WEBINAR - March 7, 2024 at 1pm ET – Rethinking therapeutic response assessment in clinical trials using ultra-sensitive ctDNA – new data and promising applications

Register now

News & Publications

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)


Back to all